SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Notably, pharmacological inhibition of eEF2K in adult mice was also sufficient to normalize the EEG profile of Scn1a ± mice proposing eEF2K as a new pharmacological target not only for Dravet syndrome but also for several neuronal diseases in which eEF2K activity is altered [50].